Surgical Robotics Patent Invalidity: FDA 510(k) Submissions and IEEE BioRobotics Prior Art
Introduction Surgical robotics sits at an unusual intersection for prior art purposes: it is simultaneously a heavily regulated medical device field and a fast-moving academic robotics discipline. That combination creates two prior art sources that patent challengers in this space rely on more heavily than in most other technology areas – FDA 510(k) submissions, generated […]
Double Patenting Rejections: How Proofreading Helps Identify Claim Overlap
Introduction Double patenting is one of the more conceptually subtle rejections a patent applicant can face, precisely because it doesn’t turn on prior art at all. It turns on the applicant’s own filings – a comparison between the claims of a pending application and the claims of another patent or application the same applicant (or […]
Prime Editing and Base Editing Patents: Sequence Listing Compliance Guide
1. Why This Topic Deserves Its Own Guide Prime editing and base editing patents are among the most sequence-dense filings in biotechnology. A single application can disclose: Because these elements don’t map neatly onto the “plain” DNA/RNA/protein sequences that WIPO Standard ST.26 was originally designed around, prime and base editing filings are unusually prone to […]
The Role of Sequence Listing Accuracy in Biotech Patent Valuation
When investors, licensees, or acquirers value a biotech patent, most of the attention goes to the obvious things: claim scope, freedom-to-operate, remaining patent term, clinical-stage progress and the competitive landscape. One component gets far less scrutiny than it deserves, given how much damage it can do – the sequence listing. For any patent disclosing nucleotide […]
PEGylated Biologics: Sequence Listing Considerations for Modified Protein Patents
Patents covering biologics – therapeutic proteins, antibodies, peptides and their derivatives – carry an obligation that small-molecule patents don’t: a formal sequence listing. When the claimed invention is a PEGylated protein, that requirement collides with a structural reality of PEGylation itself – polyethylene glycol is not an amino acid, has no place in a standard […]
Third-Party Sequence Listing Submissions in Patent Prosecution
Biotechnology patent applications occupy a unique corner of prosecution practice: the applicant’s own disclosure typically includes a formal sequence listing – a structured file of nucleotide and/or amino acid sequences that supports the claims – and much of the relevant prior art in the field consists of sequence data too, published in databases like GenBank, […]
Therapeutic Peptide Patent Applications: Sequence Listing and Claim Drafting Tips
Peptide therapeutics – from GLP-1 agonists to peptide hormones, antimicrobial peptides and cyclic peptide scaffolds – sit at an awkward intersection of patent practice: they’re chemical compounds, but they’re also defined by an amino acid sequence, which brings in a whole layer of formatting rules that small-molecule patents never have to deal with. Getting a […]
Sequence Listing Requirements in European Divisional Patent Applications
For biotech, pharma and life sciences applicants, filing a divisional application at the European Patent Office involves an extra layer of complexity that most other technology fields never encounter: the sequence listing. Since the 2022 transition to WIPO Standard ST.26, sequence listings for divisionals have become a genuine trap for the unwary – capable of […]
Transgenic Animal Patents: Sequence Listing Requirements for Genetically Modified Organisms
Patenting genetically modified animals presents a unique combination of biotechnology, patent drafting and regulatory challenges. In applications involving transgenic animals, the genetic construct may be central to the invention, while nucleotide and amino acid sequences can provide the technical detail needed to define the modification with precision. For patent applicants, however, describing a genetic sequence […]
IPO India Sequence Listing Requirements for Biotech Patent Applications
Biotechnology patent applications often contain nucleotide, amino acid, peptide, DNA, RNA, or other biological sequence information. Because these sequences can be central to the invention – and can be difficult to search and examine – the Indian Patent Office (IPO India) requires sequence disclosures to be submitted in a prescribed electronic format. For applications filed […]